BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leth JM, Leth-Espensen KZ, Kristensen KK, Kumari A, Lund Winther AM, Young SG, Ploug M. Evolution and Medical Significance of LU Domain-Containing Proteins. Int J Mol Sci 2019;20:E2760. [PMID: 31195646 DOI: 10.3390/ijms20112760] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zaigraev MM, Lyukmanova EN, Paramonov AS, Shenkarev ZO, Chugunov AO. Orientational Preferences of GPI-Anchored Ly6/uPAR Proteins. Int J Mol Sci 2022;24. [PMID: 36613456 DOI: 10.3390/ijms24010011] [Reference Citation Analysis]
2 Shenkarev ZO, Chesnokov YM, Zaigraev MM, Chugunov AO, Kulbatskii DS, Kocharovskaya MV, Paramonov AS, Bychkov ML, Shulepko MA, Nolde DE, Kamyshinsky RA, Yablokov EO, Ivanov AS, Kirpichnikov MP, Lyukmanova EN. Membrane-mediated interaction of non-conventional snake three-finger toxins with nicotinic acetylcholine receptors. Commun Biol 2022;5:1344. [PMID: 36477694 DOI: 10.1038/s42003-022-04308-6] [Reference Citation Analysis]
3 Nozue T, Tada H, Murakami M, Michishita I. A case of hyperchylomicronemia associated with GPIHBP1 autoantibodies and fluctuating thyroid autoimmune disease. Journal of Clinical Lipidology 2022. [DOI: 10.1016/j.jacl.2022.10.005] [Reference Citation Analysis]
4 Young SG, Song W, Yang Y, Birrane G, Jiang H, Beigneux AP, Ploug M, Fong LG. A protein of capillary endothelial cells, GPIHBP1, is crucial for plasma triglyceride metabolism. Proc Natl Acad Sci U S A 2022;119:e2211136119. [PMID: 36037340 DOI: 10.1073/pnas.2211136119] [Reference Citation Analysis]
5 Zhu R, Liu T, Liu F. Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor. Front Pharmacol 2022;13:754271. [DOI: 10.3389/fphar.2022.754271] [Reference Citation Analysis]
6 Brewitz L, Onisko BC, Schofield CJ. Combined proteomic and biochemical analyses redefine the consensus sequence requirement for epidermal growth factor-like domain hydroxylation. J Biol Chem 2022;:102129. [PMID: 35700824 DOI: 10.1016/j.jbc.2022.102129] [Reference Citation Analysis]
7 Alfano D, Franco P, Stoppelli MP. Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View. Front Cell Dev Biol 2022;10:818616. [DOI: 10.3389/fcell.2022.818616] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Song W, Beigneux AP, Winther AL, Kristensen KK, Grønnemose AL, Yang Y, Tu Y, Munguia P, Morales J, Jung H, de Jong PJ, Jung CJ, Miyashita K, Kimura T, Nakajima K, Murakami M, Birrane G, Jiang H, Tontonoz P, Ploug M, Fong LG, Young SG. Electrostatic sheathing of lipoprotein lipase is essential for its movement across capillary endothelial cells. J Clin Invest 2022;132:e157500. [PMID: 35229724 DOI: 10.1172/JCI157500] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Shmerling M, Chalik M, Smorodinsky NI, Meeker A, Roy S, Sagi-assif O, Meshel T, Danilevsky A, Shomron N, Levinger S, Nishry B, Baruchi D, Shargorodsky A, Ziv R, Sarusi-portuguez A, Lahav M, Ehrlich M, Braschi B, Bruford E, Witz IP, Wreschner DH. LY6S, a New Interferon-Inducible Human Member of the Ly6a-Subfamily Expressed by Spleen Cells and Associated with Inflammation and Viral Resistance.. [DOI: 10.1101/2021.12.16.472998] [Reference Citation Analysis]
10 Metrangolo V, Ploug M, Engelholm LH. The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities. Cancers (Basel) 2021;13:5376. [PMID: 34771541 DOI: 10.3390/cancers13215376] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
11 Leth JM, Ploug M. Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention. Front Cell Dev Biol 2021;9:732015. [PMID: 34490277 DOI: 10.3389/fcell.2021.732015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kristensen KK, Leth-Espensen KZ, Kumari A, Grønnemose AL, Lund-Winther AM, Young SG, Ploug M. GPIHBP1 and ANGPTL4 Utilize Protein Disorder to Orchestrate Order in Plasma Triglyceride Metabolism and Regulate Compartmentalization of LPL Activity. Front Cell Dev Biol 2021;9:702508. [PMID: 34336854 DOI: 10.3389/fcell.2021.702508] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
13 Kurbegovic S, Juhl K, Sørensen KK, Leth J, Willemoe GL, Christensen A, Adams Y, Jensen AR, von Buchwald C, Skjøth-Rasmussen J, Ploug M, Jensen KJ, Kjaer A. IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts. Theranostics 2021;11:7159-74. [PMID: 34158842 DOI: 10.7150/thno.49787] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Leth-Espensen KZ, Kristensen KK, Kumari A, Winther AL, Young SG, Jørgensen TJD, Ploug M. The intrinsic instability of the hydrolase domain of lipoprotein lipase facilitates its inactivation by ANGPTL4-catalyzed unfolding.Proc Natl Acad Sci USA. 2021;118. [PMID: 33723082 DOI: 10.1073/pnas.2026650118] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
15 Xu D, Bum-Erdene K, Leth JM, Ghozayel MK, Ploug M, Meroueh SO. Small-Molecule Inhibition of the uPAR ⋅ uPA Interaction by Conformational Selection. ChemMedChem 2021;16:377-87. [PMID: 33107192 DOI: 10.1002/cmdc.202000558] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
16 Miyashita K, Lutz J, Hudgins LC, Toib D, Ashraf AP, Song W, Murakami M, Nakajima K, Ploug M, Fong LG, Young SG, Beigneux AP. Chylomicronemia from GPIHBP1 autoantibodies. J Lipid Res 2020;61:1365-76. [PMID: 32948662 DOI: 10.1194/jlr.R120001116] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
17 Young SG, Fong LG, Beigneux AP, Allan CM, He C, Jiang H, Nakajima K, Meiyappan M, Birrane G, Ploug M. GPIHBP1 and Lipoprotein Lipase, Partners in Plasma Triglyceride Metabolism. Cell Metab 2019;30:51-65. [PMID: 31269429 DOI: 10.1016/j.cmet.2019.05.023] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 19.7] [Reference Citation Analysis]
18 Ille AM, Kishel E, Bodea R, Ille A, Lamont H, Amico-Ruvio S. Protein LY6E as a candidate for mediating transport of adeno-associated virus across the human blood-brain barrier. J Neurovirol 2020;26:769-78. [PMID: 32839948 DOI: 10.1007/s13365-020-00890-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Hayek SS, Leaf DE, Samman Tahhan A, Raad M, Sharma S, Waikar SS, Sever S, Camacho A, Wang X, Dande RR, Ibrahim NE, Baron RM, Altintas MM, Wei C, Sheikh-Hamad D, Pan JS, Holliday MW Jr, Januzzi JL, Weisbord SD, Quyyumi AA, Reiser J. Soluble Urokinase Receptor and Acute Kidney Injury. N Engl J Med 2020;382:416-26. [PMID: 31995687 DOI: 10.1056/NEJMoa1911481] [Cited by in Crossref: 92] [Cited by in F6Publishing: 96] [Article Influence: 30.7] [Reference Citation Analysis]
20 Jiang Y, Lin L, Chen S, Jiang L, Kriegbaum MC, Gårdsvoll H, Hansen LV, Li J, Ploug M, Yuan C, Huang M. Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/α-neurotoxin Domain. Int J Biol Sci 2020;16:981-93. [PMID: 32140067 DOI: 10.7150/ijbs.39919] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Weidemann DK, Abraham AG, Roem JL, Furth SL, Warady BA. Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children. Am J Kidney Dis 2020;76:194-202. [PMID: 31987488 DOI: 10.1053/j.ajkd.2019.11.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]